ProfileGDS5678 / 1429180_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 40% 44% 69% 53% 37% 51% 65% 62% 60% 68% 54% 58% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.722262
GSM967853U87-EV human glioblastoma xenograft - Control 22.9249540
GSM967854U87-EV human glioblastoma xenograft - Control 33.0321644
GSM967855U87-EV human glioblastoma xenograft - Control 44.3041769
GSM967856U87-EV human glioblastoma xenograft - Control 53.2384553
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9418737
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.311651
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.8723365
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7084262
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5966960
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.1987368
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2877654
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5183858
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8360964